Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Virpax Pharmaceuticals, Inc. (VRPX : OTC)

• Company Description    Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals Inc. is based in WEST CHESTER, PA. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $0.37 Daily Weekly Monthly 20 Day Moving Average: 13,488 shares Shares Outstanding: 1.24 (millions) Market Capitalization: $0.46 (millions) Beta: 1.58 52 Week High: $3.77 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 52.93% 47.19% 12 Week 23.37% 1.51% Year To Date -96.10% -96.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1055 Westlakes Drive Suite 300 - Berwyn,PA 19312 USA ph: 610-727-4597 fax: - betsy.brod@affinitygrowth.com http://www.virpaxpharma.com

• General Corporate Information    Officers Jatinder Dhaliwal - Chief Executive Officer Usama Chaudhry - Chief Financial Officer Katharyn Field - Director Charn Deol - Director Judy Su - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 928251305 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 1.24 Most Recent Split Date: 3.00 (0.04:1) Beta: 1.58 Market Capitalization: $0.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 91.57% vs. Previous Quarter: 75.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - -636.70 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.63 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.63 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - -1.53 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©